In the interview with Life Science Review, NTC CEO Riccardo Carbucicchio highlighted NTC's commitment to producing drugs that fill patients' unmet medical needs...
The deal represents an important step for the internationalization of NTC015, developed to address unmet medical needs and improve patient compliance.
NTC, an international pharmaceutical company headquartered in Milan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems
The combination has been registered in nearly 60 countries for the prevention and treatment of inflammation and the prevention of infection associated with cataract surgery in adults. It is currently marketed in 50 countries worldwide.